Dr. Pusztai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
300 George St, New Haven
Suite 120
New Haven, CT 06520Fax+1 203-785-5792- Is this information wrong?
Education & Training
University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1996 - 1999
Rochester Regional Health/Unity Hospital (Rochester)Residency, Internal Medicine, 1992 - 1996
Semmelweis UniversityClass of 1986
Certifications & Licensure
TX State Medical License 1997 - 2025
CT State Medical License 2012 - 2024
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACP) American College of Physicians, 2003
Clinical Trials
- Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients Start of enrollment: 2001 Jan 01
- Vinorelbine With or Without Trastuzumab in Treating Women With Progressive Metastatic Breast Cancer Start of enrollment: 2004 Dec 01
- Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer Start of enrollment: 2003 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.Alejandro Ríos-Hoyo, Thomas A Buchholz, Laura Esserman, Laura J van 't Veer, Erin Cobain, Laura A Huppert, Peter D Beitsch, Hope S Rugo, Lajos Pusztai> ;Journal of Clinical Oncology. 2024 Apr 9
- Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.Elias, A., Kathy S Albain, Christina Yau, Emanuel F Petricoin, Denise M Wolf, Julie E Lang, A Jo Chien, Tufia Haddad, Andres Forero-Torres, Anne M Wallace, Henry Kapla...> ;Clinical Cancer Research. 2024 Feb 16
- Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast C...Chowdhury Arif Jahangir, David B Page, Glenn Broeckx, Claudia A Gonzalez, Caoimbhe Burke, Clodagh Murphy, Jorge S Reis-Filho, Amy Ly, Paul W Harms, Rajarsi R Gupta, Mi...> ;The Journal of Pathology. 2024 Mar 1
- Join now to see all
Journal Articles
- Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women with ERBB2 (HER2)–Positive Breast CancerLajos Pusztai, MD, JAMA Network Open
- Association of T-cell Receptor Repertoire Use with Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast CancerSecondary Analysis of the NeoALTT...Lajos Pusztai, Jose Baselga, JAMA
Lectures
- Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- Why Do We Care About Molecular Evolution in Breast Cancer?2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- 2013 Breast Cancer Symposium,American Society of Breast Surgeons, San Francisco, California - 9/7/2013
Press Mentions
Connecticut Magazine’s 2023 “Top Doctors” Issue Recognizes 82 Smilow Cancer Hospital and Yale Cancer Center PhysiciansMay 1st, 2023- Discoveries & Impact (March 2023)March 16th, 2023
- Two Simple Biomarkers Could Differentiate Which Young Women with ER+ Breast Cancer Need ChemotherapyNovember 14th, 2022
- Join now to see all
Professional Memberships
- Member
- Fellow
Hospital Affiliations
Yale-New Haven HospitalNew Haven, Connecticut
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
